These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34129318)

  • 1. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy.
    Li Y; Yi J; Ma R; Wang Y; Lou X; Dong Y; Cao Y; Li X; Wang M; Dang X; Li R; Lei N; Song H; Qin Z; Yang W
    J Control Release; 2024 Sep; 373():447-462. PubMed ID: 39038546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
    Heo MB; Cho MY; Lim YT
    Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
    Liu Y; Crowe WN; Wang L; Lu Y; Petty WJ; Habib AA; Zhao D
    Nat Commun; 2019 Nov; 10(1):5108. PubMed ID: 31704921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of RIG-I/MDA5 Signaling and Inhibition of CD47-SIRPα Checkpoint with a Dual siRNA-Assembled Nanoadjuvant for Robust Cancer Immunotherapy.
    Xu X; Li S; Yu W; Yao S; Fan H; Guo Z
    Angew Chem Int Ed Engl; 2024 Mar; 63(10):e202318544. PubMed ID: 38194267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
    Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
    Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment.
    Lee S; Hong KH; Park H; Ha J; Lee SE; Park DJ; Jeong SD; Kim S; Kim D; Ahn J; Lee HW; Koh WG; Ha SJ; Kim YC
    J Control Release; 2024 Sep; 373():55-69. PubMed ID: 38971428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity.
    Xie Y; Li K; Liang J; Wang K; Gong Z; Chen X
    Int J Pharm; 2024 Apr; 654():123955. PubMed ID: 38423155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment.
    Wang Z; Miao F; Gu L; Zhang R; Ma Y; Li Y; Zheng J; Lin Z; Gao Y; Huang L; Shen Y; Wu T; Luo F; Li W
    ACS Nano; 2024 Sep; 18(35):24219-24235. PubMed ID: 39172516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth.
    Shaji SG; Patel P; Mamani UF; Guo Y; Koirala S; Lin CY; Alahmari M; Omoscharka E; Cheng K
    Int J Nanomedicine; 2024; 19():8769-8778. PubMed ID: 39220196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.